Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.5600 on 2017-11-17

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert

2017-10-10

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Management

Price: $55.400
Owned: Yes

2017-06-15

BUY on WEAKNESS
Abbott Labs (ABT-N)

She continues to hold it and likes it.  They have done well this year so she would wait for a pull back to add to this position.  They are good at taking costs out.  They always increase their dividend and it should continue.  A good core holding.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $48.120
Owned: Yes

2017-05-17

TOP PICK
Abbott Labs (ABT-N)

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Management

Price: $43.080
Owned: Yes

2017-05-10

COMMENT
Abbott Labs (ABT-N)

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $44.500
Owned: No

2017-03-21

BUY
Abbott Labs (ABT-N)

This fits the profile of the type of company he would want to be adding to, on days like today. It is in the sector that is tremendously out of favour. The healthcare sector was the only sector that had a negative return last year. It has started to be a little more resilient this year, but relative to the history of healthcare, valuations are far more reasonable. He likes this because it has a history and a culture of growing the dividend. They have a wonderful brand name. 2.4% dividend yield.

biotechnology/pharmaceutical
David Dietze

Founder, Pres. & Chief Investment Strategist, Point View Wealth Management

Price: $44.800
Owned: Unknown

2017-02-22

COMMENT
Abbott Labs (ABT-N)

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $45.010
Owned: Unknown

2016-09-13

WAIT
Abbott Labs (ABT-N)

This does branded generics, nutritionals and medical devices. Their branded generics have good exposure to emerging markets, areas that need the drugs but don’t necessarily have the money to pay for the branded version. A well diversified company run by great management. They have announced 2 acquisitions. The overhang on the stock is that if they do both transactions, they may have to issue equity to fund some of that.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $40.640
Owned: Yes

2016-08-17

COMMENT
Abbott Labs (ABT-N)

Healthcare is one of the sectors in the broad N.A. market that is heavily out of favour. This is in the healthcare and equipment space, and is not one of those business that is deeply, deeply undervalued right now. It is in the process of trying to do a merger, and he is very reticent about recommending a stock that is in the process of having a merger in the US. He would much prefer an Allergan (AGN-N) where there is no potential deal risk at all. Abbott Labs is trading at 20X this year’s earnings, and Allergan is trading at about 18X, and is a much bigger growth story. Dividend yield of 2.33%. (See Top Picks.)

biotechnology/pharmaceutical
Bruce Tatters

Founding Partner and CIO, Triumph Asset Management

Price: $44.680
Owned: Unknown

2016-07-28

DON'T BUY
Abbott Labs (ABT-N)

Significant emerging markets exposure.  He sees better risk reward in other parts of the healthcare market.

biotechnology/pharmaceutical
Andy Nasr

VP & Investment Strategist, Sentry Investments

Price: $44.450
Owned: No

2016-06-22

COMMENT
Abbott Labs (ABT-N)

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $38.740
Owned: Yes

2016-06-14

BUY
Abbott Labs (ABT-N)

Acquiring St. Jude Medical to enhance their stent products, and Alere, which is a diagnostic company. The stock pulled back when they announced the St. Jude acquisition, as it is quite large. The company will probably have to issue some equity to fund both acquisitions. She really likes management. This is an attractive entry point.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $37.660
Owned: Yes

2016-06-01

BUY
Abbott Labs (ABT-N)

Has not performed very well of late. He likes it going forward as well as their acquisition of St. Jude’s Medical, which will be accretive to the bottom line. This would be a nice time to pick up some shares.

biotechnology/pharmaceutical
Matthew McCall

President, Penn Financial Group

Price: $39.500
Owned: Unknown

2016-05-18

COMMENT
Abbott Labs (ABT-N)

Emerging markets represents about 40% of their earnings. Have a very strong branded generic division and a lot of that is in the emerging-market, so currency has been a huge head wind for them. Also, have a leading adult and infant nutritional business as well as medical devices. There was some concern that the medical device area was not growing as fast as some of their other businesses. Management is quite competent they can get things improving.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $37.750
Owned: Yes

2016-05-11

DON'T BUY
Abbott Labs (ABT-N)

Healthcare is a great sector, but the worst performing one year-to-date. Politicians are talking about capping prices for healthcare manufacturers, which doesn’t help. More importantly, Medicare and Medicaid US administrations are trying to cap prices and this one is being hit particularly hard. There are better names in this space.

biotechnology/pharmaceutical
John Burke

CEO & CIO, Burke Financial Strategies

Price: $38.010
Owned: Unknown

2016-02-09

COMMENT
Abbott Labs (ABT-N)

Abbott Labs (ABT-N) or Johnson & Johnson (JNJ-N)? She likes healthcare as an overall investment because of the demographics. They both have FX headwinds because they are both international. Emerging markets is about 40% of this company’s revenues. If you want a diversified health care company that gives you an attractive yield, she would go with J&J.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $37.000
Owned: Yes

2016-02-04

BUY on WEAKNESS
Abbott Labs (ABT-N)

He likes it.  Everything under healthcare has been under pressure.  Model $39 with a 3% upside.  At $31 he would be very excited.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $38.010
Owned: Unknown

2015-09-17

COMMENT
Abbott Labs (ABT-N)

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $44.240
Owned: No

2015-05-05

COMMENT
Abbott Labs (ABT-N)

Right now this is more if a consumer and diagnostic company. Has done quite well. Is very, very steady. Have increased their dividends 43 years in a row. A nice holding for somebody who wants to buy something and just stay with it over the long-term. However, the valuation is not cheap. Well-managed and should do well over the long-term.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $46.850
Owned: No

2015-04-27

BUY on WEAKNESS
Abbott Labs (ABT-N)

He would wait for some sort of correction. Likes this. It is a leader in its field.

biotechnology/pharmaceutical
Peter Brieger

Chairman & Chief Executive Officer, GlobeInvestment Capital Management

Price: $47.490
Owned: Yes

2015-03-05

COMMENT
Abbott Labs (ABT-N)

Has a really good upward trend. It is a little above trend right now. Great long-term chart. Healthcare is a great long-term trend that we are in, and you can’t go wrong. It will probably come back a little bit, but nothing to worry about.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $47.440
Owned: No

2014-11-11

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Oct 29/13. Up 22.2%.) A diversified health company. About 40% of their branded generic business is in emerging markets. They expect to increase that percentage. Also, a large player in the nutritional business. Their 3rd division is medical devices and diagnostics.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $44.250
Owned: Yes

2014-10-14

TOP PICK
Abbott Labs (ABT-N)

Spinning off another division. He loves the drug space, which is free of volatility. His model price is $45, a 10% upside.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $41.060
Owned: Yes

2014-10-07

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Oct 29/13. Up 13.13%.) A diversified global healthcare company. They have 4 divisions including brand generics which is more focused on emerging markets. Also, have a nutritional business as well as a stents division along with the diagnostic division. Pays a dividend of about 2%.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $41.460
Owned: Yes

2014-09-17

TOP PICK
Abbott Labs (ABT-N)

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $43.380
Owned: Yes

2014-08-29

COMMENT
Abbott Labs (ABT-N)

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.

biotechnology/pharmaceutical
Jennifer Radman

VP & Sr. Portfolio Manager, Caldwell Investment Management

Price: $42.240
Owned: No

2014-07-08

PAST TOP PICK
Abbott Labs (ABT-N)

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out.  This is where the growth is.  They have branded generics which are a growth area in emerging markets.  The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $41.050
Owned: Yes

2014-04-09

DON'T BUY
Abbott Labs (ABT-N)

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $37.630
Owned: No

2014-02-18

BUY
Abbott Labs (ABT-N)

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns

Price: $38.930
Owned: Yes

2014-02-07

BUY
Abbott Labs (ABT-N)

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.

biotechnology/pharmaceutical
Michael Bowman

Portfolio Manager, Wickham Investment Management

Price: $37.180
Owned: Unknown

2014-02-04

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $36.250
Owned: Yes

Showing 1 to 30 of 106 entries
<< < 1 2 3 4 > >>

No Comments.


You must be logged in to comment.